A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

This study tests a new oral drug called JBI-802, alone or combined with an immunotherapy drug (pembrolizumab), for people with advanced non-small cell lung cancer that carries a specific genetic change called an STK11 mutation. **You may be eligible if...** - You are 18 or older - You have been diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an STK11 gene mutation - Your blood counts and organ function (liver, kidneys) meet required levels - You have at least one measurable tumor on a scan - Your overall health is good enough to carry out daily activities (ECOG score 0–2) - You are able to swallow pills - You are willing to use contraception during and for at least 3 months after treatment **You may NOT be eligible if...** - You received cancer treatment or an investigational drug within the last 2 weeks - You had major surgery within the last 3 weeks - You have unstable brain metastases or are on steroids for brain swelling - You have serious heart problems (e.g., recent heart attack, severe arrhythmia, or significant heart failure) - You have a condition that affects how you absorb oral medications - You received a live vaccine in the last 30 days - You are taking strong medications that interact with certain liver enzymes (CYP3A or CYP2D6) Talk to your doctor to see if this trial is right for you.